The current price of EDIT is $2.56 — it has increased by 0.20% since the previous close. Data as of Nov 6, 2026.
EDIT is down 11.94% over the past week, down 6.78% over the past month and down 5.39% over the past year. The price is below its 200-day moving average of $2.69.
Analysts' average 12-month price target for EDIT is $5.50, which implies 115.26% upside from the current price. Individual estimates range from $5.00 to $6.00.
Of the 13 analysts covering Editas Medicine, Inc., 9 rate it a buy, 2 rate it a hold and 2 rate it a strong sell. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Editas Medicine, Inc. has a market capitalization of $392.4M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Editas Medicine, Inc. posted a loss of $0.15 per share against an estimate of -$0.2705, beating expectations by 44.55%. Upcoming reports are listed in the earnings calendar.
Editas Medicine, Inc. reported revenue of $11.89M in its most recent quarter, which has increased by 232.31% compared with the same quarter a year earlier. Analysts had expected $2.85M.
Companies most comparable to Editas Medicine, Inc. include CRISPR Therapeutics AG, Beam Therapeutics Inc., Intellia Therapeutics, Inc., Prime Medicine, Inc. and Benitec Biopharma Inc.
In the latest trading session EDIT moved between $2.48 and $2.63, a range of 5.87% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Editas Medicine, Inc. shows a sell rating today and a strong sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Editas Medicine, Inc. is strong sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks EDIT has traded between $1.66 and $3.94. The current price is 35.15% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.